When a CAR hits the blood 

Post-CAR T management in aggressive B-cell lymphoma

Webinar: 55 minutes

When a CAR hits the blood – what happens next matters. Listen to key takeaways from Dr. Kai Rejeski

• Toxicities following CAR‑T therapy in lymphoma
• Evidence‑based insights into immune effector cell–associated hematotoxicity (ICAHT) and prolonged cytopenias
• Risk stratification and prediction of post‑CAR‑T hematologic toxicity
• Practical tools to support clinical decision‑making, including the CAR‑HEMATOTOX score

The session is moderated by Prof. Mats Hellström.